Loading...
XNAS
ESPR
Market cap736mUSD
Dec 05, Last price  
3.73USD
1D
-1.58%
1Q
39.18%
Jan 2017
-70.21%
IPO
-74.28%
Name

Esperion Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:ESPR chart
P/E
—
P/S
2.22
EPS
—
Div Yield, %
—
Shrs. gr., 5y
47.19%
Rev. gr., 5y
17.50%
Revenues
332m
+185.66%
02,00000004,977,012,0000000184,474,000148,364,000227,547,00078,447,00075,475,000116,334,000332,314,000
Net income
-52m
L-75.27%
-10,670,184-27,576,000-24,931,000-28,726,000-10,817,341-11,741,736-26,088,133-36,375,000-49,784,000-74,978,000-166,988,000-201,810,000-109,022,000-166,189,000-318,824,000-287,817,000-209,248,000-51,745,000
CFO
-24m
L-82.54%
-7,852,572-17,954,000-22,767,000-26,564,000-9,068,725-10,808,567-18,113,361-32,021,000-38,156,000-47,730,000-131,302,000-148,638,000-70,341,000-85,177,000-263,809,000-174,827,000-135,487,000-23,654,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
URL
https://www.esperion.com/
IPO date
Jun 24, 2013
Employees
199
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT